MGMaria Luisa Guerrera

Maria Luisa Guerrera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Luisa Guerrera has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of initial dosing and subsequent dose reduction of zanubrutinib in patients with Waldenström macroglobulinemia

    by Alberto Guijosa, Nicolò Danesin, Nickolas Tsakmaklis, Margaret Kobs, Amanda Kofides, Maria Luisa Guerrera, Zachary R Hunter, Andrew R. Branagan, Camille V. Edwards, Tarek H. Mouhieddine, et al.

    Zanubrutinib is the preferred Bruton tyrosine kinase inhibitor for Waldenström macroglobulinemia (WM), yet data on dosing strategies remain limited. We evaluated 236 WM patients who received zanubrutinib monotherapy between 2018 and 2025. We assessed the impact of initial dosing and subsequent dose reductions on very good partial response (VGPR) and progression-free survival (PFS). Multivariate logistic and Cox models identified independent predictors of VGPR and PFS. Among 236 patients, 193 (82%) initiated 160 mg twice-daily, 22 (9%) initiated 320 mg daily, and 21 (9%) initiated sub-standard-dosing (<320 mg daily). With a median follow-up of 33 months (95% CI, 30.4-35.2), standard-dose regimens produced comparable outcomes: VGPR 39% (71/184) with 160 mg twice-daily vs. 40% (8/20) with 320 mg daily (p=0.90), and 30-month PFS rate 89% vs. 89% (p=0.86). Sub-standard initiation yielded inferior efficacy, with VGPR of 14% (3/21; p=0.03) and a 30-month PFS rate of 54% (p<0.001). In multivariable analysis, sub-standard-dose initiation independently predicted lower VGPR attainment (OR 0.10; p=0.04) and worse PFS (HR 11.09; p=0.001). In contrast, subsequent, toxicity-driven, dose reductions after standard-dose initiation that occurred in 51/215 (24%), patients did not worsen outcomes (VGPR 49% vs. 36%, p=0.09; 30-month PFS rate 95% vs. 88%, p=0.13) and improved symptoms in 34/51 (67%), particularly for rheumatologic and gastrointestinal toxicities. In conclusion, findings from this largest off-trial WM cohort support standard-dose zanubrutinib initiation with either 320 mg daily or 160 mg twice daily, while suggesting that dose reductions may be better reserved for toxicity management after standard-dose initiation rather than used preemptively.

  • Open Access

    Chemoimmunotherapy‐associated CD20 ( MS4A1 ) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies

    by Alberto Guijosa, Nickolas Tsakmaklis, Sirano Dhe‐Paganon, Filip Garbicz, Ruben Carrasco, John Hatcher, Andres Ramirez‐Gamero, Dominic Pizzarella, Amanda Kofides, Shirong Liu, et al.

  • Open Access

    Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells

    by Dominic Pizzarella, Amanda Kofides, John M. Hatcher, Xia Liu, Alberto Guijosa, Nickolas Tsakmaklis, Abigail L. Peachey, Jinhua Wang, Maria Luisa Guerrera, Christopher J. Patterson, et al.


  • Open Access

    WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström’s Macroglobulinemia

    by Maria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, Abigail L. Peachey, Amanda Kofides, John Hatcher, Andres Ramirez Gamero, Alberto Guijosa, Guang Yang, Hao Sun, et al.

    WNK2 is a known tumor suppressor in a set of solid tumors, including glioblastoma multiforme and pancreatic ductal adenocarcinoma. WNK2 functions are largely unknown beyond the kinase domain (KD)-dependent inhibition of ERK1/2 signaling. Waldenström’s Macroglobulinemia (WM) is an indolent, yet incurable, B cell lymphoma characterized by highly recurrent MYD88 (MYD88MUT) and CXCR4 (CXCR4MUT) mutations that trigger sustained NF-κB and ERK1/2 signaling. Although not expressed in healthy B cells, WNK2 is a top dysregulated gene in MYD88MUT WM. To study WNK2 regulation and signaling, we performed multi-omics analyses, including bulk and PacBio Iso-Seq RNA-Seq and methylome, in 264 untreated WM and functional studies in cell lines and primary WM cells. Aberrant expression of WNK2 emerged as a near universal feature of early-stage WM and a hallmark of plasma cell-like MYD88MUT WM. We identified novel isoforms that carried a shared aberrant splicing event, either contained or lacked the KD and were highly expressed by the tumor cells, unlike the canonical full-length isoforms. Functionally, WNK2/S-NK1, the most expressed of the KD-lacking isoforms in WM, triggered a pro-inflammatory cascade that activated ERK1/2 and NF-κB signaling. We observed a similar, cancer-specific upregulation of WNK2 in a set of solid tumors, including the highly aggressive cholangiocarcinoma. Our findings reveal an undocumented oncogenic function for WNK2 driven by novel, cancer-specific isoforms and provide a framework for its further investigation as a determinant of disease progression in MYD88MUT WM and a novel therapeutic target in hematological and solid tumor oncology.

  • Top Cited Papers

    Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia

    by Hao Sun, Romanos Sklavenitis-Pistofidis, Shirong Liu, Xia Liu, Nicholas Tsakmaklis, John M. Hatcher, Maria Luisa Guerrera, Amanda Kofides, Andres Ramirez-Gamero, Abigail L. Peachey, et al.

    To elucidate the molecular basis underlying differential responses and resistance to ibrutinib in Waldenström macroglobulinemia (WM), we conducted a prospective phase 2 trial of ibrutinib monotherapy in treatment-naïve patients. A total of 74 sequential bone marrow (BM) aspirates from 17 patients, collected from baseline through 48 treatment cycles, were profiled using single-cell multiomics. BM cells were segregated primarily into B-cell/plasma cell and T-cell compartments. Longitudinal clonal tracking of malignant B cells/plasma cells identified 3 distinct evolutionary patterns: evolution (early clone contraction with late clone expansion and increasing genomic complexity), devolution (early clone expansion with late clone contraction and genomic simplification), and no evolution (stable clonal architecture). The evolution pattern was strongly associated with disease progression, whereas devolution correlated with durable clinical response. Transcriptomic profiling of resistant clones enabled development and validation of the Waldenström ibrutinib prediction (WIP) score, which predicted treatment response at baseline. Within the WIP signature, LYN emerged as a key regulator; LYN knockdown or inhibition significantly increased WM cell sensitivity to ibrutinib, suggesting a rational combination strategy. In parallel, GZMB+ CD8+ effector-memory T cells expanded after treatment in patients with progressive disease and coexisted with tumor evolution. These cells exhibited persistently impaired cytotoxic programs (eg, GNLY), a dedifferentiated memory-like state, elevated PDCD1 expression, and reduced T-cell receptor diversity. Together, this study provides, to our knowledge, the first single-cell framework of tumor clonal evolution and T-cell dysfunction under ibrutinib in WM, introduces the WIP score as a predictive biomarker for treatment response, and identifies actionable tumor-intrinsic and immune mechanisms driving resistance. This trial was registered at www.ClinicalTrials.gov as NCT02604511.


  • Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

    by Jorge J. Castillo, Andrew R. Branagan, Alberto Guijosa, Gottfried von Keudell, Andres Ramirez‐Gamero, Hannah Chory, Margaret Kobs, Nina Budano, Julia Nguyen, Alexandra Eurell, et al.

    The BTK inhibitor ibrutinib and the BCL‐2 antagonist venetoclax are active therapies as single agents in Waldenström macroglobulinemia (WM). In this phase 2 study, we sought to investigate the combination of ibrutinib and venetoclax as a 2‐year fixed‐duration, oral‐based, chemotherapy‐free regimen in symptomatic, treatment‐naive WM patients. All patients had MYD88 mutations, 17 (38%) had CXCR4 mutations, and 4 (9%) had TP53 alterations. Following enrollment of 45 patients, treatment and enrollment were stopped due to the occurrence of ventricular arrhythmias in 4 (9%), which included two grade 5 events. The median treatment time was 10 cycles, each lasting 28 days. Follow‐up continued after protocol treatment was terminated. The very good partial response/complete response (VGPR/CR) rate was 42%, and it was lower in patients with CXCR4 (29% vs. 50%) or TP53 (25% vs. 44%) mutations. With a median follow‐up of 49 months, the median progression‐free survival (PFS) was 36 months (range 28–42). The median treatment‐free survival (TFS) and overall survival (OS) were not reached, and the 4‐year TFS and OS rates were 73% and 91%, respectively. The median PFS after end of therapy (PFS‐EOT) was 29 months. TP53 mutations were associated with inferior PFS, TFS, and PFS‐EOT, while CXCR4 mutations did not adversely impact these outcomes. Given the deep and durable responses seen in this study, concurrent BTK and BCL‐2 inhibition warrants further development in WM. TP53 mutations emerged as an adverse factor in WM in this combination study.


  • Open Access

    Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom macroglobulinemia

    by Nickolas Tsakmaklis, Zachary R. Hunter, Xia Liu, Amanda Kofides, Shirong Liu, Maria Luisa Guerrera, Alberto Guijosa, Hao Sun, John M. Hatcher, Abigail Peachey, et al.

  • Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterations

    by Alberto Guijosa, Nicholas Tsakmaklis, Margaret Kobs, Amanda Kofides, Maria Luisa Guerrera, Gottfried von Keudell, Andrew Branagan, Zachary R. Hunter, Steven P. Treon, Shayna Sarosiek, et al.


  • Open Access

    Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenström macroglobulinemia

    by Andres Ramirez-Gamero, Nicholas Tsakmaklis, Zachary R. Hunter, Maria Luisa Guerrera, Alberto Guijosa, Shayna Sarosiek, Steven P. Treon, Jorge J. Castillo

    Approximately 20% of patients with Waldenström macroglobulinemia (WM) report family history (FH) of hematologic malignancies. However, the impact of FH on patient outcomes remains unclear. We included 1000 patients with WM to determine the relationship between FH, characteristics, complications, and treatment outcomes. Data collected included clinical features at diagnosis, complications (Bing-Neel syndrome [BNS], aggressive transformation, AL [light chain] amyloidosis, and neuropathy), FH cluster (WM [WM-FH], other B-cell FH [B-FH], non–B-cell FH [NON–B-FH], and sporadic [NO-FH]), and treatment outcomes. Logistic regression models were fitted to estimate the odds of complications. Time-to-event outcomes were assessed using the Kaplan-Meier method, and differences between groups evaluated using the log-rank test. Proportional hazards Cox regression models were fitted to determine the impact of WM-FH on time to first treatment (TTFT), overall survival (OS), and survival after first treatment initiation (SAFTI). The NO-FH group was the reference group for the regression analyses. The median follow-up time from diagnosis was 13 years. There were more women in the WM-FH than in the NO-FH group (50% vs 34%; P< .01). In multivariate logistic regression analysis, WM-FH was associated with higher odds of BNS (odds ratio [OR], 3.90; P = .005) and lower odds of neuropathy (OR, 0.49; P = .03) than NO-FH. The median TTFT was 0.7 years, OS was 23 years, and SAFTI was 20.5 years for all patients. In multivariate Cox regression analyses, WM-FH did not affect TTFT, SAFTI, or OS. Our study suggests higher odds of BNS and lower odds of neuropathy in patients with WM-FH but no impact of WM-FH on TTFT, OS, or SAFTI.


  • A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis

    by Jorge J. Castillo, Shayna R Sarosiek, Andrew R. Branagan, Gottfried von Keudell, Catherine A. Flynn, Nina S Budano, Alexandra N. Eurell, Kirsten Meid, Andres Ramirez-Gamero, Maria Luisa Guerrera, et al.

    Background: BTK inhibitors and BCL2 antagonists as monotherapy are highly active and well tolerated in Waldenström macroglobulinemia (WM). Non-covalent BTK inhibitors have shown efficacy in WM patients progressing on covalent BTK inhibitors. However, BTK inhibitor therapy has an indefinite duration with cumulative toxicity and risk of developing resistance. We initiated a prospective study evaluating the novel non-covalent BTK inhibitor pirtobrutinib in combination with the BCL2 antagonist venetoclax given as a fixed-duration regimen in previously treated WM. Methods: This was an investigator-initiated, multicenter, prospective phase II study in symptomatic, previously treated WM patients (ClinicalTrials.gov ID NCT05734495). Study therapy was given in 4-week cycles. Intended therapy consists of pirtobrutinib at 200 mg/day on cycle 1. Venetoclax is added on cycle 2 at 100 mg/day for one week, 200 mg/day for one week, and 400 mg/day for two weeks, followed by pirtobrutinib 200 mg/day and venetoclax 400 mg/day given together for cycles 3-24. Patients undergo baseline laboratory studies, a bone marrow biopsy with MYD88, CXCR4, and TP53 genotyping, and CT scans of the chest, abdomen, and pelvis to evaluate extramedullary disease. The outcome of interest was attaining a very good partial response (VGPR) or better. Responses are assessed using modified IWWM6 criteria. Assumptions included H0 15%, H1 35%, 2-sided alpha 0.03, and power 0.85 for a sample size of 42 patients. The null hypothesis will be rejected if 12 or more patients attain a VGPR or better. For this interim analysis, if 3 VGPR or better events or fewer were observed in the first 16 patients, the study should be stopped early because of futility, with a probability of stopping early of 79%. Results: Between May 2023 and June 2024, 16 (8 males; 8 females) patients have been enrolled. Baseline characteristics include median age 67 (range 57-76 years), median number of previous therapies 1 (range 1-3), previous covalent BTK inhibitor 9 (56%), previous rituximab-containing regimens 11 (69%), median serum IgM 2,401 (range 551-7,249 mg/dL), median hemoglobin 8.6 (range 6.6-11.5 g/dL), median bone marrow involvement 80% (20-90%), lymphadenopathy (>1.5 cm) 7 (44%), and splenomegaly (>15 cm) 2 (13%). MYD88 L265P was detected in 14 patients (88%), CXCR4 mutations in 6 (38%), and TP53 mutations in 1 (6%). The median study follow-up is 6 months (range 3-12). VGPR was attained in 9 patients (56%), partial response in 5 (31%), and minor response in 2 (13%), for an overall response rate of 100%. No complete responses were observed. CXCR4 mutations (33% v 70%; p=0.35) and previous exposure to covalent BTK inhibitors (33% v 86%; p=0.05) might be associated with lower VGPR rates. The median time to VGPR was 1.9 months (95% CI 0.9-2.2). CXCR4 mutations (p=0.32) and previous exposure to covalent BTK inhibitors (p=0.50) did not seem to impact time to VGPR. At best response, median serum IgM decreased to 254 (range 35-3786 mg/dl; p<0.001), median hemoglobin increased to 12.1 (range 8.2-16.2 g/dl); p<0.001), and median bone marrow involvement decreased to 0% (range 0-40%; p<0.001) when compared to baseline. Of the seven patients with lymphadenopathy, 5 (71%) had improvement or resolution, and of the two patients with splenomegaly, 2 (100%) had improvement or resolution. Two patients had disease progression at two and five months; both had MYD88 WT disease. The 6-month progression-free survival rate is 84% (95% CI 49-96%), and the 6-month overall survival rate is 93% (95% CI 61-99). There have been no arrhythmia events thus far. Conclusion: The combination of pirtobrutinib and venetoclax appears active in symptomatic, previously treated WM patients with a VGPR rate of 56%, exceeding the futility rate. CXCR4 mutations and previous exposure to covalent BTK inhibitors might impact VGPR rates. Accrual will continue to enroll 26 additional patients.